Structural Modifications of Salicylates: Inhibitors of Human CD81‐Receptor HCV‐E2 Interaction
作者:Marcel Holzer、Sigrid Ziegler、Alexander Neugebauer、Bernd Kronenberger、Christian D. Klein、Rolf W. Hartmann
DOI:10.1002/ardp.200700261
日期:2008.8
extracellular loop (LEL) of the CD81‐receptor (crystal structure: PDB‐ID: 1G8Q). After benzyl salicylate had been experimentally validated to be a moderate inhibitor of the CD81‐LEL–HCV‐E2 interaction, further optimization was performed and heterocyclic‐substituted benzyl salicylate derivatives were synthesized. The compounds were tested for their ability to inhibit the interaction of a fluorescence‐labeled
本文的出发点是使用 CD81 受体(晶体结构:PDB-ID:1G8Q)的大细胞外环(LEL)的开放构象进行虚拟筛选的结果。在实验证实水杨酸苄酯是 CD81-LEL-HCV-E2 相互作用的温和抑制剂后,进行了进一步优化并合成了杂环取代的水杨酸苄酯衍生物。使用 HUH7.5 细胞测试了这些化合物抑制荧光标记抗体与 CD81-LEL 相互作用的能力。与水杨酸苄酯相比,没有化合物显示出抑制蛋白质-蛋白质相互作用的增加。